The semaglutide group of drugs: what sits in it, and what that means for you

Which brands actually carry semaglutide, and why it matters

The molecule semaglutide exists inside three licensed UK products, each with a separate marketing authorisation and a specific purpose. Wegovy (the weekly injection made by Novo Nordisk) is licensed for weight management in adults with a BMI of 30 or above, or 27 and above where a weight-related health condition is present. The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, carries the same active ingredient in a formulation designed to be absorbed through the gut wall when taken on an empty stomach.

Ozempic is also a weekly semaglutide injection, but its UK licence covers type 2 diabetes, not weight management. Rybelsus is the oral semaglutide tablet for type 2 diabetes, the 3 mg, 7 mg and 14 mg strengths it uses are entirely separate from the Wegovy tablet's weight-management dosing schedule. Mixing these up is one of the most common misunderstandings our prescribers encounter, and it matters because using a medicine outside its licensed indication is both legally complex and clinically risky. The NHS medicines page for semaglutide sets out the licensed uses clearly and is worth a read before any consultation.

So when someone searches for the semaglutide drugs available in the UK, they are often really asking: which of these products is right for me? The answer starts with the purpose (weight management or diabetes) and then moves into the clinical detail a prescriber reviews.

How semaglutide compares with others in the broader GLP-1 family

Semaglutide shares its mechanism with other GLP-1 receptor agonists, including liraglutide (Saxenda, licensed for weight management; Victoza, for diabetes) and exenatide. All activate the GLP-1 receptor, prompting the pancreas to release insulin in response to food, slowing gastric emptying, and signalling the brain to reduce appetite. The differences lie in dosing frequency, how long the molecule stays active in the body, and the trial evidence behind each.

Tirzepatide, sold in the UK as Mounjaro, is closely related but distinct: it activates both the GLP-1 and the GIP receptors. That dual action places it in a different pharmacological category. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks. The newer Wegovy 7.2 mg dose (approved by the MHRA in early 2026) narrows that gap somewhat, reaching around 20.7% average weight loss in trials. Neither figure applies universally; individual results vary, and a prescriber will discuss realistic expectations with you.

If you are trying to decide between medicines in this broader class, the comparison of drugs similar to semaglutide on this site walks through the differences in plain terms.

What the prescriber's decision tree actually looks like

A prescriber reviewing suitability for any drug in the semaglutide group is not simply ticking a BMI box. They consider whether the goal is weight management or blood-sugar control, current medications (some interact with GLP-1 agonists), personal and family medical history (certain thyroid conditions and a history of pancreatitis require careful thought), kidney function, and whether the patient is pregnant, breastfeeding, or trying to conceive, semaglutide is not recommended in any of those situations, nor is it licensed for under-18s.

The injectable versus oral question is increasingly relevant now that the Wegovy tablet exists. Oral semaglutide must be taken first thing in the morning on an empty stomach, with only a small amount of plain water, waiting at least 30 minutes before food, drink, or other medicines, a routine that suits some people far better than a weekly injection, and others less so. Neither is inherently superior; the right format depends on a person's lifestyle, tolerability, and how reliably they can follow the instructions. You can read more about the full semaglutide treatment options available in the UK before your consultation.

Cost is also a genuine factor for many people. Private pricing for semaglutide-based treatment varies by dose, format, and provider. For a grounded look at what figures are actually involved, the Wegovy pricing guide covers the honest market context, including what a legitimate price should include beyond the medicine itself.

How the NHS and private routes diverge for this group

NICE has recommended Wegovy (injection) for NHS use under specific conditions: a specialist weight management service, a maximum treatment duration of two years, and a BMI of at least 35 with one or more weight-related conditions, with lower thresholds applying for some ethnic backgrounds under UK guidance. If you want to understand how those criteria apply in practice, our Wegovy group page explains the full picture, including how the different products within that family are positioned. In practice, NHS waiting lists for those services can be long, and the phased rollout means many people who are clinically eligible are still waiting.

For that reason, many people turn to regulated private providers. The important thing is that the route stays legitimate: semaglutide products are prescription-only medicines under UK law, and buying them from a seller who offers them without a formal clinical assessment puts you at serious risk, not just legally, but physically. The MHRA has warned repeatedly about counterfeit injectable pens circulating online, some containing the wrong substance entirely. Verifying any online pharmacy on the GPhC register takes under a minute and is the single most useful check you can do.

At nume, every consultation for a semaglutide-group medicine is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated software. If treatment is clinically appropriate, it is dispatched the same day for free next-working-day tracked delivery. The weight management treatment overview explains what that process looks like from your first click.

If you are considering combining semaglutide with other treatments, our page on BPC-157 and semaglutide covers what the evidence currently says about using them together. If you are ready to talk through which medicine in this class might suit you, speak to our prescribers through a free consultation today.